Shenzhen Accord Pharmaceutical Co., Ltd.
The Third Quarterly Report for 2011(Full Text)
§1. Important Notes
1.1 Board of Directors and the Supervisory Committee of Shenzhen Accord Pharmaceutical Co.,
Ltd. (hereinafter referred to as the Company) and its directors, supervisors and senior executives
hereby confirm that there are no any fictitious statements, misleading statements, or important
omissions carried in this report, and shall take all responsibilities, individual and/or joint, for the
reality, accuracy and completion of the whole contents.
1.2 Except for the followed directors, others were attended the Meeting in person for deliberating
the third quarterly report.
Name of absent Name of
Title Reason of absence
directors entrusted
Lu Jun Director Due to business Wu Aimin
Jiang Xiuchang Director Due to business Wu Aimin
He Zhiyi Independent Director Due to health Xiong Chuxiong
1.3The Third Quarterly Financial Report of 2011 has not been audited by CPAs.
1.4 Chairman of the Board Mr. Shi Jinming, General Manager Mr. Yan Zhigang, CFO Mr. Wei
Pingxiao and Financial Manager Mr. Chi Guoguang hereby confirm that the Financial Report of the
Third Quarterly Report is true and complete.
§2. Company Profile
2.1 Main accounting highlights and financial indexes:
Unit: RMB
Increase/decrease
2011.9.30 2010.12.31
scope (%)
Total assets (RMB) 7,323,929,954.43 6,306,793,005.81 16.13%
Owners’ equities attributable to
the shareholders of listed company 1,265,860,415.42 1,052,370,309.53 20.29%
(RMB)
Share capital (Share) 288,149,400.00 288,149,400.00 0.00%
Net assets per share attributable to
the shareholders of listed company 4.393 3.652 20.29%
(RMB/Share)
Increase/decreas Increase/decreas
e over the same e over the same
July-Sept.2011 Jan.-Sept. 2011
period of the last period of the last
year (%) year (%)
3,926,991,975.3 11,122,364,393.
Total operating income (RMB) 13.78% 14.80%
9 15
Net profit attributable to the
shareholders of listed company 81,101,590.05 33.77% 246,238,033.89 36.79%
(RMB)
Net cash flow arising from
- - -189,951,324.31 -167.47%
operating activities (RMB)
Net cash flow arising from
operating activities per share - - -0.66 -167.47%
(RMB/Share)
Basic earnings per share
0.28 33.33% 0.85 37.10%
(RMB/Share)
1
Diluted earnings per share
0.28 33.33% 0.85 37.10%
(RMB/Share)
Weighted average return on equity
6.68% 0.49% 21.16% 1.75%
(%)
Weighted average return on equity
after deducting non-recurring 6.39% 0.28% 19.70% 1.04%
gains/losses (%)
Items of non-recurring gains and losses
√Applicable □Inapplicable
Unit: RMB
Remarks (If
Items of non-recurring gains and losses Amount
applicable)
Gains and losses from the disposal of non-current
2,855,132.14
asset
Governmental subsidy calculated into current gains
and losses, while closely related with the business
of the Company, excluding the fixed-amount or 9,171,958.05
fixed-proportion governmental subsidy according
to the unified national standard
Switched back of impairment provision of account
receivable that performed impairment testing 3,822,967.87
independently.
Other non-operating income and expense excluded
6,768,301.37
the aforementioned business
Influenced amount of minority shareholders’
-1,156,331.42
gains/losses
Impact on income tax -4,502,192.51
Total 16,959,835.50 -
2.2 Total number of shareholders at the end of the report period and shares held by the top
ten shareholders with unrestricted conditions
Unit: Share
Total number of shareholders
14,711
at the end of report period
Particulars about the shares held by the top ten shareholders with unrestricted conditions
Unrestricted shares held at
Full name of shareholder Type of shares
period-end
SINOPHARM GROUP CO., LTD. 110,459,748 RMB common share
ICBC－GUANGFA JUFENG
12,140,955 RMB common share
STOCK FUND
ICBC—Harvest Theme New
10,290,292 RMB common share
Power Stock Fund
AGRICULTURAL BANK OF
CHINA－GREATWALL ANXIN 8,198,537 RMB common share
RETURN MIXED FUND
HTHK/CMG FSGUFP-CMG
Domestically listed foreign
FIRST STATE CHINA GROWTH 7,032,720
share
FD
ICBC—GUANGFA STRATEGY 4,207,399 RMB common share
2
SELECTED MIX STOCK FUND
ICBC— HARVEST STRATEGY
4,103,442 RMB common share
GROWTH MIX STOCK FUND
ICBC—China Universal Balance
3,897,565 RMB common share
Growth Stock Fund
ICBC—China Universal Health
3,467,015 RMB common share
Care Stock Fund
China Construction Bank –
Huabao Industrial Profit Growth 3,449,986 RMB common share
Mix Security Fund
§3. Significant events
3.1 Particulars about material changes in items of main accounting statement and financial
index, and explanations of reasons
√Applicable □Inapplicable
1. Note receivable: increase RMB 141.29 million at period-end over that of period-begin with an
increase rate of 38.27%. Main reasons caused by the growth of sale income and the note amount
recovery increased.
2. Construction in progress: increase RMB 81.46 million at period-end over that of period-begin
with an increase rate of 75.22%. Mainly caused by: RMB 58.73 million was increased for the
newly project of logistic garden for Guangxi Sinopharm Logistic, the subsidiary of the Company
and RMB 21.17 million invested in the plant project that newly establish for subsidiary of the
Company—Zhijun Wanqing and Zhijun Pharmaceutical.
3. Short-term loans: increase RMB 541.47 million at period-end over that of period-begin with an
increase rate of 55.51%. Mainly caused by: the amount for goods were difficult to recover due to
the influence of macro-control; the Company enlarge financing scale for guarantee the business
back into normal development.
4. Note payable: decrease RMB 453.11 million at period-end over that of period-begin with an
increase rate of -31.28%. Mainly because in this period, other settlement instruments were adopted
by the Company broadly, and reduced the settlement with notes.
5. Account payable: increase RMB 642.22 million at period-end over that of period-begin with an
increase rate of 32.05%. Mainly because the growth of sales stimulated the growth of purchasing,
this brings more balance in account payable.
6. Account receivable: decrease RMB 50.43 million at period-end over that of period-begin with an
increase rate of -50.27%. Mainly because account received in advance that satisfied income
reorganization principal at period-begin have been transfer to sales income.
7. Taxes payable: increase RMB 20.17 million at period-end over that of period-begin with an
increase rate of 50.77%. Mainly because vary taxes were increase due to the stimulation from
soaring sales income and profitability, furthermore, higher tax rate of city construction tax and
income tax in Shenzhen has a certain influence on taxes payable.
8. Interest payable: increase RMB 3.76 million at period-end over that of period-begin with an
increase rate of 177.25%. Mainly because enlargement of financing scale brings more interest
payable.
9. Long-term loans: increase RMB 58.09 million at period-end over that of period-begin with an
increase rate of 193.64%. Mainly because newly debt financing of RMB 43.09 million and RMB 15
million were newly increased for establishment of logistic garden project of Guangxi Sinopharm
Logistic, subsidiary of the Company and for expansion of plant of Zhijun Wanqing, subsidiary of
the Company increased.
10. Business tax and extra: gains a y-o-y growth of RMB 11.73 million with an increase rate of
3
84.40%. Mainly caused by the factors of VAT that increased according to the soaring sales as well
as the higher city construction tax rate.
11. Financial expenses: gains a y-o-y growth of RMB 37.14 million with an increase rate of
63.64%. Mainly because: on one hand loan rates higher with the influence of tight-money policy of
the State; on the other hand financing cost soaring due to the expansion of financing scale.
12. Losses of assets impairment: decrease RMB 12.39 million y-o-y with an increase rate of
-64.52%. Mainly because in this year, the Company take strengthen management on credit and
inventory turnover for clients, receivable bad debt provision and inventory depreciation provision
were decreased.
13. Non-operating income: gains a y-o-y growth of RMB9.75 million with an increase rate of
100%. Mainly because: in this period, the Company received more government grants than same
period of last year, furthermore, part of the account payable, remain historically and no need to
paid, has been disposed in this period.
14. Non-operating expenditure: decrease RMB 2.58 million y-o-y with an increase rate of -89.75%.
Mainly because at same period of last year, there are more disaster relief donation and more
disposal of fixed assets from the Company and its subordinated companies.
15. Net profit: gains a y-o-y growth of RMB65.92 million with an increase rate of 36.07%. Mainly
because: the Company controlling its expenditures reasonably for higher products’ gross profit
which upgrade the profitability correspondingly.
16. Other cash received from operating activity: decrease RMB 64.56 million y-o-y with an
increase rate of -43.14%. Mainly because in this year, item of income from other business was
collected for adjustment.
17. Net cash flow arising from operating activity: decrease RMB 471.49 million y-o-y with an
increase rate of -167.47%. Mainly because affected by the country’s financial environment, account
received in a slow status; meanwhile, in order to satisfy sales scales expansion, the purchasing
expenditures increased.
18. Cash received from investment income: gains a y-o-y growth of RMB9.32 million with an
increase rate of 112.71%. Mainly because: Main Luck Pharmaceuticals, associated company, gains
a y-o-y growth in net profit of 2010, the Company gains a corresponding growth in equity.
19. Net cash received from disposal of subsidiary and other operating units: decrease RMB 0.33
million y-o-y with an increase rate of -100%. Mainly because in year of 2010, subsidiary of the
Company—Zhijun Pharmaceutical gains an amount from equity sales of Shenzhen Associated
Guangshen Pharmaceutical, and there are no such business occurred in this year.
20. Other cash received from investment activity: decrease RMB 15 million y-o-y with an increase
rate of -100%. Mainly because at same period of last year, Shenzhen TCM, subsidiary of the
Company, received amount from Sino-TCM that borrowed previously, and there are no such
business occurred in this period.
21. Cash paid for investment: decrease RMB 13.34 million y-o-y with an increase rate of -100%.
Mainly because at same period of last year, capital increased amount (before consolidation) to
Shenzhen Yanfeng, subsidiary of the Company, and previously two phases of equity acquisition
amount of Sinopharm Meizhou, subsidiary of the Company, were paid by the Company, and there
are no such business occurred in this period.
22. Net cash paid for receiving subsidiary and other operating units: decrease RMB 5.26 million
y-o-y with an increase rate of -47.88%. Mainly because at same period of last year, purchasing
amount of Shenzhen Yanfeng and Sinopharm Meizhou, subsidiary of the Company, were paid by
the Company; in this year, except for paying the last amount of equity purchasing of 2010, no such
acquisition business occurred.
23. Other cash paid for investment activity: decrease RMB 56.30 million y-o-y with an increase
rate of -85.19%. Mainly because at same period of last year, subsidiary of the Company, Sinopharm
Nanning paid large part of the purchasing amount for acquisition of Nanning Medicine Company,
4
rests of the payment was paid in this period.
24. Cash received from borrowings: decrease RMB 596.58 million y-o-y with an increase rate of
-45.94%. Mainly because affected by tight-money policy of the State, loan rate goes up, Company
minimized its loan scales with purpose of lower its financing cost, and adopted other financing
instrument instead.
25. Other cash received from financing activity: gains a y-o-y growth of RMB630.57 million with
an increase rate of 4742.93%.Mainly because the Company broadly adopted supply chain financing
instrument in order to supporting sales.
26. Cash paid for debts paying: decrease RMB 780.53 million y-o-y with an increase rate of
-63.18%. Mainly because borrowing scale has a y-o-y down that reduce debt payment.
27. Cash paid for distribution of dividend, profit or interest payment: gains a y-o-y growth of
RMB28.62 million with an increase rate of 40.46%. Mainly because the financing scale
enlargement stimulated the financing cost increased.
28. Other cash paid for financing activities: gains a y-o-y growth of RMB563.35 million with an
increase rate of 2315.09%.Mainly because return of the financing amount by supply chain saw a
y-o-y rise in this year.
3.2 Progress of significant events, their influences, and analysis and explanation of their
solutions
3.2.1 Qualified opinion
□Applicable √Inapplicable
3.2.2 Particular about fund offers to controlling shareholders or associated parties and
external guarantee that against the regulation.
□Applicable √Inapplicable
3.2.3 Particular about signing and implementation on significant contracts of ordinary
management.
□Applicable √Inapplicable
3.2.4 Other
□Applicable √Inapplicable
3.3 Implementations of commitments by the Company, shareholders and actual controller
Commitments made by the listed company and its directors, supervisors, senior executives, the
shareholders with holding above 5% shares and its actual controller in the report period or lasting
until the report period.
□Applicable √Inapplicable
3.4 Estimation of accumulative net profit from the beginning of the year to the end of next
report period to be loss probably or the warning of its material change compared with the
corresponding period of the last year and explanation of reason
□Applicable √Inapplicable
3.5 Particulars about the other significant events which needed explanations
3.5.1 Particular about security investment
□Applicable √Inapplicable
5
3.5.2 Activities on receiving research, communication and interview in the report period
In the report period, there were no receiving spot research, communication and written inquiry from
the investors.
3.6 Particulars about derivatives investment
□Applicable √Inapplicable
3.6.1 Particulars about the positions of derivatives investment at the end of report period
□Applicable √Inapplicable
§4. Appendix
4.1 Balance sheet
Prepared by Shenzhen Accord Pharmaceutical Co., Ltd. Sept. 30, 2011 Unit: RMB
Balance at period-end Balance at year-begin
Items
Consolidation Parent Company Consolidation Parent Company
Current assets:
Monetary funds 579,744,090.30 157,668,011.21 711,789,775.66 135,498,819.87
Settlement provisions
Capital lent
Transaction finance
asset
Notes receivable 510,458,556.15 10,317,191.04 369,169,030.47 5,038,459.89
Accounts receivable 3,667,489,777.70 309,149,677.12 2,866,825,102.78 282,597,465.23
Accounts paid in
121,833,618.63 1,405,993.16 101,806,030.92 3,798,560.90
advance
Insurance receivable
Reinsurance
receivables
Contract reserve of
reinsurance receivable
Interest receivable
Dividend receivable
Other receivables 36,408,190.09 519,379,359.45 43,110,999.74 557,324,957.67
Purchase restituted
finance asset
Inventories 1,279,606,910.61 127,333,995.29 1,156,329,658.80 117,829,120.30
Non-current asset due
within one year
Other current assets
Total current assets 6,195,541,143.48 1,125,254,227.27 5,249,030,598.37 1,102,087,383.86
Non-current assets:
Granted entrusted
loans and advances
Finance asset
available for sales
Held-to-maturity
investment
Long-term account
receivable
Long-term equity
88,950,423.95 1,325,677,838.04 85,275,251.06 1,272,402,665.15
investment
Investment real estate 83,389,595.91 9,158,439.50 87,293,333.76 12,033,619.61
Fixed assets 475,178,911.45 34,108,597.53 492,557,743.43 35,677,614.01
6
Construction in
189,762,107.45 253,886.24 108,301,338.12 253,886.24
progress
Engineering material
Disposal of fixed asset
Productive biological
asset
Oil and gas asset
Intangible assets 117,612,091.07 27,849,493.56 129,175,366.09 28,837,698.02
Expense on Research
3,269,317.10 2,580,662.85
and Development
Goodwill 53,555,677.09 53,555,677.09
Long-term expenses
21,231,763.25 8,924,314.88 19,811,611.24 9,161,222.49
to be apportioned
Deferred income tax
37,202,133.97 3,354,842.32 31,083,592.24 2,958,699.75
asset
Other non-current
58,236,789.71 48,127,831.56 0.00
asset
Total non-current asset 1,128,388,810.95 1,409,327,412.07 1,057,762,407.44 1,361,325,405.27
Total assets 7,323,929,954.43 2,534,581,639.34 6,306,793,005.81 2,463,412,789.13
Current liabilities:
Short-term loans 1,516,943,964.58 463,605,676.79 975,475,884.21 349,183,556.07
Loan from central
bank
Absorbing deposit and
interbank deposit
Capital borrowed
Transaction financial
liabilities
Notes payable 995,505,160.92 110,275,720.89 1,448,622,490.72 227,394,114.09
Accounts payable 2,645,787,834.74 311,281,992.43 2,003,566,517.62 238,636,669.29
Accounts received in
49,894,715.68 664,663.33 100,322,387.21 48,490.62
advance
Selling financial asset
of repurchase
Commission charge
and commission payable
Wage payable 135,302,239.75 33,598,135.72 127,191,717.25 22,612,110.63
Taxes payable 59,886,702.33 7,681,747.19 39,720,311.72 2,957,612.62
Interest payable 5,884,066.02 773,878.62 2,122,314.90 596,047.97
Dividend payable
Other accounts
359,183,446.29 667,342,020.29 345,011,293.80 874,380,433.82
payable
Reinsurance payables
Insurance contract
reserve
Security trading of
agency
Security sales of
agency
Non-current liabilities
due within one year
Other current liabilities
Total current liabilities 5,768,388,130.31 1,595,223,835.26 5,042,032,917.43 1,715,809,035.11
Non-current liabilities:
Long-term loans 88,091,853.63 30,000,000.00
Bonds payable
7
Long-term account
36,846.60 40,777.80
payable
Special accounts
4,519,000.00 1,032,000.00 4,755,000.00 1,320,000.00
payable
Projected liabilities
Deferred income tax
20,938,663.80 3,773,319.00 22,709,093.70 3,773,319.00
liabilities
Other non-current
94,595,803.19 75,809,855.74
liabilities
Total non-current liabilities 208,182,167.22 4,805,319.00 133,314,727.24 5,093,319.00
Total liabilities 5,976,570,297.53 1,600,029,154.26 5,175,347,644.67 1,720,902,354.11
Owner’s equity (or
shareholders’ equity):
Paid-in capital (or
288,149,400.00 288,149,400.00 288,149,400.00 288,149,400.00
share capital)
Capital public reserve 5,030,338.57 13,828,726.93 5,030,338.57 13,828,726.93
Less: Inventory shares
Reasonable reserve
Surplus public reserve 39,981,268.55 39,981,268.55 39,981,268.55 39,981,268.55
Provision of general
risk
Retained profit 932,699,408.30 592,593,089.60 719,209,302.41 400,551,039.54
Balance difference of
foreign currency
translation
Total owner’s equity
attributable to parent 1,265,860,415.42 934,552,485.08 1,052,370,309.53 742,510,435.02
company
Minority interests 81,499,241.48 79,075,051.61
Total owner’s equity 1,347,359,656.90 934,552,485.08 1,131,445,361.14 742,510,435.02
Total liabilities and
7,323,929,954.43 2,534,581,639.34 6,306,793,005.81 2,463,412,789.13
owner’s equity
4.2 Profit statement in the report period
Prepared by Shenzhen Accord Pharmaceutical Co., Ltd. July-Sept.2011 Unit: RMB
Amount in this period Amount in last period
Items
Consolidation Parent Company Consolidation Parent Company
I. Total operating income 3,926,991,975.39 520,183,508.48 3,451,455,784.19 475,039,013.02
Including: Operating
3,926,991,975.39 520,183,508.48 3,451,455,784.19 475,039,013.02
income
Interest income
Insurance gained
Commission charge
and commission income
II. Total operating cost 3,832,988,264.86 534,326,861.12 3,376,938,613.12 480,283,148.59
Including: Operating cost 3,606,934,783.70 493,296,835.21 3,162,038,837.76 450,682,693.73
Interest expense
Commission charge
and commission expense
Cash surrender value
Net amount of
expense of compensation
Net amount of
withdrawal of insurance
contract reserve
8
Bonus expense of
guarantee slip
Reinsurance expense
Operating tax and
10,037,431.51 1,167,722.05 5,157,804.62 688,756.01
extras
Sales expenses 90,409,469.47 10,542,164.77 110,688,869.08 15,209,431.95
Administration
90,577,777.13 17,951,497.63 74,154,927.01 6,978,798.06
expenses
Financial expenses 34,088,871.51 11,470,667.32 21,002,277.66 7,565,774.18
Losses of devaluation
939,931.54 -102,025.86 3,895,896.99 -842,305.34
of asset
Add: Changing
income of fair value(Loss
is listed with “-”)
Investment income
8,459,883.59 8,459,883.59 6,316,035.43 4,915,955.21
(Loss is listed with “-”)
Including: Investment
income on affiliated 8,459,883.59 8,459,883.59 6,316,035.43 4,915,955.21
company and joint venture
Exchange income
(Loss is listed with “-”)
III. Operating profit
102,463,594.12 -5,683,469.05 80,833,206.50 -328,180.36
(Loss is listed with “-”)
Add: Non-operating
4,481,813.60 3,054,118.66 1,034,347.08 201,318.79
income
Less: Non-operating
77,727.87 3.97 2,030,478.53 304,222.56
expense
Including: Disposal
39,743.32 0.00 43,976.25 10,332.02
loss of non-current asset
IV. Total Profit (Loss is
106,867,679.85 -2,629,354.36 79,837,075.05 -431,084.13
listed with “-”)
Less: Income tax
25,930,899.43 2,129,973.08 20,060,652.38 251,620.26
expense
V. Net profit (Net loss is
80,936,780.42 -4,759,327.44 59,776,422.67 -682,704.39
listed with “-”)
Net profit attributable
to owner’s of parent 81,101,590.05 -4,759,327.44 60,629,253.89 -682,704.39
company
Minority shareholders’
-164,809.63 0.00 -852,831.22 0.00
gains and losses
VI. Earnings per share:
i. Basic earnings per share 0.28 0.00 0.21 0.00
ii. Diluted earnings per
0.28 0.00 0.21 0.00
share
VII. Other consolidated
income
VIII. Total consolidated
80,936,780.42 -4,759,327.44 59,776,422.67 -682,704.39
income
Total consolidated income
attributable to owners of 81,101,590.05 -4,759,327.44 60,629,253.89 -682,704.39
parent company
Total consolidated income
attributable to minority -164,809.63 0.00 -852,831.22 0.00
shareholders
The merging party realized net profit of RMB 00.00 before consolidation under same control in this
period.
9
4.3 Profit statement from year-begin to the end of report period
Prepared by Shenzhen Accord Pharmaceutical Co., Ltd. Jan.-Sept. 2011 Unit: RMB
Amount in this period Amount in last period
Items
Consolidation Parent Company Consolidation Parent Company
I. Total operating income 11,122,364,393.15 1,466,936,940.92 9,688,283,303.16 1,353,859,049.12
Including: Operating
11,122,364,393.15 1,466,936,940.92 9,688,283,303.16 1,353,859,049.12
income
Interest income
Insurance gained
Commission charge
and commission income
II. Total operating cost 10,838,251,351.99 1,498,753,601.64 9,468,646,564.80 1,373,346,648.57
Including: Operating cost 10,126,675,089.61 1,394,818,434.22 8,837,874,229.04 1,288,553,523.09
Interest expense
Commission charge
and commission expense
Cash surrender value
Net amount of
expense of compensation
Net amount of
withdrawal of insurance
contract reserve
Bonus expense of
guarantee slip
Reinsurance expense
Operating tax and
25,636,443.23 3,079,873.50 13,902,386.62 1,199,539.38
extras
Sales expenses 330,211,835.54 35,131,140.36 320,305,854.08 39,476,480.54
Administration
253,416,823.08 37,283,777.36 219,000,977.41 30,214,858.66
expenses
Financial expenses 95,495,577.80 28,289,487.66 58,355,589.10 16,830,524.35
Losses of devaluation
6,815,582.73 150,888.54 19,207,528.55 -2,928,277.45
of asset
Add: Changing
income of fair value(Loss
is listed with “-”)
Investment income
21,270,172.89 256,330,651.56 17,620,749.32 232,345,086.43
(Loss is listed with “-”)
Including: Investment
income on affiliated 21,270,172.89 21,270,172.89 17,579,508.02 14,167,184.29
company and joint venture
Exchange income
(Loss is listed with “-”)
III. Operating profit
305,383,214.05 224,513,990.84 237,257,487.68 212,857,486.98
(Loss is listed with “-”)
Add: Non-operating
19,497,223.63 5,636,496.77 9,742,859.08 1,105,951.89
income
Less: Non-operating
294,922.39 3.97 2,878,021.15 306,022.56
expense
Including: Disposal
109,996.54 515,586.66 10,332.02
loss of non-current asset
IV. Total Profit (Loss is
324,585,515.29 230,150,483.64 244,122,325.61 213,657,416.31
listed with “-”)
Less: Income tax
75,923,291.53 5,360,505.58 61,381,449.43 1,890,403.72
expense
V. Net profit (Net loss is 248,662,223.76 224,789,978.06 182,740,876.18 211,767,012.59
10
listed with “-”)
Net profit attributable
to owner’s of parent 246,238,033.89 224,789,978.06 180,016,350.27 211,767,012.59
company
Minority shareholders’
2,424,189.87 2,724,525.91
gains and losses
VI. Earnings per share:
i. Basic earnings per share 0.85 0.62
ii. Diluted earnings per
0.85 0.62
share
VII. Other consolidated
0.00 0.00 0.00
income
VIII. Total consolidated
248,662,223.76 224,789,978.06 182,740,876.18 211,767,012.59
income
Total consolidated income
attributable to owners of 246,238,033.89 224,789,978.06 180,016,350.27 211,767,012.59
parent company
Total consolidated income
attributable to minority 2,424,189.87 2,724,525.91
shareholders
The merging party realized net profit of RMB 00.00 before consolidation under same control that
occurred from year-begin to end of this period.
4.4 Cash flow statement from year-begin to the end of report period
Prepared by Shenzhen Accord Pharmaceutical Co., Ltd. Jan.-Sept. 2011 Unit: RMB
Amount in this period Amount in last period
Items
Consolidation Parent Company Consolidation Parent Company
I. Cash flows arising from
operating activities:
Cash received from
selling commodities and 10,511,426,420.78 1,582,721,158.31 9,773,477,475.48 1,453,119,356.08
providing labor services
Net increase of
customer deposit and
interbank deposit
Net increase of loan
from central bank
Net increase of capital
borrowed from other
financial institution
Cash received from
original insurance contract
fee
Net cash received
from reinsurance business
Net increase of
insured savings and
investment
Net increase of
disposal of transaction
financial asset
Cash received from
interest, commission
charge and commission
Net increase of capital
borrowed
11
Net increase of
returned business capital
Write-back of tax
1,037,653.73 844,711.99 41,418.25
received
Other cash received
concerning operating 85,101,605.22 13,528,398.19 149,660,381.44 37,025,200.44
activities
Subtotal of cash
inflow arising from 10,597,565,679.73 1,596,249,556.50 9,923,982,568.91 1,490,185,974.77
operating activities
Cash paid for
purchasing commodities 9,955,439,884.19 1,590,198,109.09 8,815,594,782.32 1,378,094,218.87
and receiving labor service
Net increase of
customer loans and
advances
Net increase of
deposits in central bank
and interbank
Cash paid for original
insurance contract
compensation
Cash paid for interest,
commission charge and
commission
Cash paid for bonus
of guarantee slip
Cash paid to/for staff
322,310,193.51 31,799,371.78 282,327,715.80 23,015,277.02
and workers
Taxes paid 265,869,197.00 17,415,084.04 220,975,219.47 20,057,438.40
Other cash paid
concerning operating 243,897,729.34 37,825,100.83 323,543,137.56 69,869,275.34
activities
Subtotal of cash
outflow arising from 10,787,517,004.04 1,677,237,665.74 9,642,440,855.15 1,491,036,209.63
operating activities
Net cash flows arising
-189,951,324.31 -80,988,109.24 281,541,713.76 -850,234.86
from operating activities
II. Cash flows arising from
investing activities:
Cash received from
1,830,000.00 1,830,000.00 45,000,000.00
recovering investment
Cash received from
17,595,000.00 96,016,500.73 8,271,829.94 32,048,822.01
investment income
Net cash received
from disposal of fixed,
4,063,113.42 3,239,648.92 5,574,171.08 3,400.00
intangible and other
long-term assets
Net cash received
from disposal of 325,415.00
subsidiaries and other units
Other cash received
concerning investing 251,989,281.47 15,000,000.00 1,611,038.60
activities
Subtotal of cash
23,488,113.42 353,075,431.12 29,171,416.02 78,663,260.61
inflow from investing
12
activities
Cash paid for purchasing
fixed, intangible and other 139,500,985.77 3,360,428.22 134,908,779.92 1,104,146.37
long-term assets
Cash paid for
55,321,335.24 13,337,330.00 596,797,330.00
investment
Net increase of
mortgaged loans
Net cash received
from subsidiaries and other 5,721,335.24 10,976,615.51 36,186,250.63
units
Other cash paid
concerning investing 9,784,633.68 213,544,100.00 66,085,417.90 2,236,560.24
activities
Subtotal of cash
outflow from investing 155,006,954.69 272,225,863.46 225,308,143.33 636,324,287.24
activities
Net cash flows arising
-131,518,841.27 80,849,567.66 -196,136,727.31 -557,661,026.63
from investing activities
III. Cash flows arising
from financing activities:
Cash received from
absorbing investment
Including: Cash
received from absorbing
minority shareholders’
investment by subsidiaries
Cash received from
702,060,383.69 270,000,000.00 1,298,635,652.93 790,000,000.00
loans
Cash received from
issuing bonds
Other cash received
concerning financing 643,866,835.40 949,038,879.26 13,294,996.81 1,325,952,632.75
activities
Subtotal of cash
inflow from financing 1,345,927,219.09 1,219,038,879.26 1,311,930,649.74 2,115,952,632.75
activities
Cash paid for settling
454,940,493.30 210,000,000.00 1,235,465,730.35 800,000,000.00
debts
Cash paid for
dividend and profit
99,358,778.12 81,268,773.85 70,737,430.86 56,361,505.91
distributing or interest
paying
Including: Dividend
and profit of minority
1,489,758.64
shareholder paid by
subsidiaries
Other cash paid
concerning financing 587,681,155.37 905,462,372.49 24,333,723.30 731,655,502.04
activities
Subtotal of cash
outflow from financing 1,141,980,426.79 1,196,731,146.34 1,330,536,884.51 1,588,017,007.95
activities
Net cash flows arising
203,946,792.30 22,307,732.92 -18,606,234.77 527,935,624.80
from financing activities
IV. Influence on cash and -13,288.37 -2,701.01 -2,383.85
13
cash equivalents due to
fluctuation in exchange
rate
V. Net increase of cash and
-117,536,661.65 22,169,191.34 66,796,050.67 -30,578,020.54
cash equivalents
Add: Balance of cash
and cash equivalents at the 682,875,873.18 135,498,819.87 588,405,672.15 125,541,203.80
period -begin
VI. Balance of cash and
cash equivalents at the 565,339,211.53 157,668,011.21 655,201,722.82 94,963,183.26
period -end
4.5 Auditor’s report
Auditor’s opinions: Un-audited
14
